08 Mar Safety clinical trials with NexPlasmaGen’s technology start!
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology
Montreal / March 08, 2025 – The Centre hospitalier de l’Université de Montréal (CHUM) site has been activated to begin recruiting patients for safety trials with NexPlasmaGen’s medical technology for the treatment of breast cancer.
NexPlasmaGen is pleased to participate in these clinical trials, the primary aim of which is to confirm the safety of its medical technology, the Convertible Plasma Jet (CPJ) for the treatment of breast cancer. These trials will take place at the CHUM in Montreal and will involve up to 30 patients. These clinical trials also aim to gather results on the effectiveness of this technology in destroying breast cancer cells in human breast tissue.
At the same time as these clinical trials are taking place, NexPlasmaGen is scaling up its technology so that it is ready for clinical efficacy trials for the treatment of breast cancer. These trials will begin once the safety trials have been completed. The goal of treatment with NexPlasmaGen’s medical technology is to reduce local recurrence of breast cancer.
ABOUT NEXPLASMAGEN
NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.
Contact
Valérie Léveillé, CEO/Founder
1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/
No Comments